Placeholder

LabCentral Houses Scientific Visionaries
Engaged in Early-Stage Research

Vedere Bio, Inc.

Vedere is developing cutting-edge gene therapy products to restore functional vision to patients who have suffered vision loss from Inherited Retinal Degenerations (IRDs), as well as other causes of both genetic and non-genetic vision loss. While the vast majority of ocular gene therapies only limit the rate of inevitable vision loss, we aim to restore lost vision regardless of a patient’s underlying genetics or their stage of disease.

  • Kevin Bitterman, PhD Chairman of the Board
  • Cyrus D. Mozayeni Founder and CEO
  • Eileen McCullough SVP, Operations and Corporate Strategy
  • Karen Guerin, PhD Director of Virology